EMEA-002969-PIP01-21
Key facts
| Active substance |
|
| Therapeutic area |
Other
|
| Decision number |
P/0249/2021
|
| PIP number |
EMEA-002969-PIP01-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic kidney disease
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AstraZeneca AB
Tel. +46 8 553 24400 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|